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Abstract
Purpose This review provides an overview of the current challenges in oral targeted antineoplastic drug (OAD) dosing and
outlines the unexploited value of therapeutic drug monitoring (TDM). Factors influencing the pharmacokinetic exposure in OAD
therapy are depicted together with an overview of different TDM approaches. Finally, current evidence for TDM for all approved
OADs is reviewed.
Methods A comprehensive literature search (covering literature published until April 2020), including primary and secondary
scientific literature on pharmacokinetics and dose individualisation strategies for OADs, together with US FDA Clinical
Pharmacology and Biopharmaceutics Reviews and the Committee for Medicinal Products for Human Use European Public
Assessment Reports was conducted.
Results OADs are highly potent drugs, which have substantially changed treatment options for cancer patients. Nevertheless,
high pharmacokinetic variability and low treatment adherence are risk factors for treatment failure. TDM is a powerful tool to
individualise drug dosing, ensure drug concentrations within the therapeutic window and increase treatment success rates. After
reviewing the literature for 71 approved OADs, we show that exposure-response and/or exposure-toxicity relationships have
been established for the majority. Moreover, TDM has been proven to be feasible for individualised dosing of abiraterone,
everolimus, imatinib, pazopanib, sunitinib and tamoxifen in prospective studies. There is a lack of experience in how to best
implement TDM as part of clinical routine in OAD cancer therapy.
Conclusion Sub-therapeutic concentrations and severe adverse events are current challenges in OAD treatment, which can both
be addressed by the application of TDM-guided dosing, ensuring concentrations within the therapeutic window.
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Introduction
With the approval of imatinib in 2001 [1], kinase inhibitors
(KIs) have significantly improved the prognosis of many can-
cers. As of April 2020, 71 oral antineoplastic drugs (OADs)
targeting a large assortment of molecular targets
(Supplementary Fig. 1) are approved by the European
Medicines Agency (EMA) and/or the US Food and Drug
Administration (FDA).
With more OADs available, both the route of administra-
tion and the treatment setting are changing. While i.v. chemo-
therapy is mainly administered in an in-patient setting, OADs
allow outpatient care with both its advantages and disadvan-
tages. Strong advantages are the level of independence, and,
due to outpatient treatment, a reduction of health care costs. At
the same time, the responsibility for adhering to treatment
schedules is moved to the patient. Given the often-complex
treatment regimens, patients must be well trained and moti-
vated to take their medication correctly. Moreover, patients
should have knowledge on the frequency and severity of pos-
sible adverse events (AEs) and on preventive and responsive
measures to limit them. Yet, adherence to targeted OADs is
variable.
Other aspects to consider are the complex pharmacokinet-
ics (PK) of OADs [2]. Although the right drug (‘what’) is
increasingly selected based on the tumour characteristics, a
fixed dose (‘how much’) is mostly given in OADs, leading
to large differences between individual plasma concentrations.
High interindividual variability (IIV) in exposure at standard
dosing, mostly ranging from 19 to 100% [3] and up to 16-fold
for gefitinib [4], has been described for OADs. While modern
phase I studies increasingly assess exposure-response rela-
tionships and maximum tolerated doses (MTD) become
harder to identify, the fixed dose for a new antineoplastic drug
is historically established in a phase I study using a 3 + 3
design, which focuses on toxicity [5]. The MTD, defined as
the dose level below the toxic dose level, is usually adopted as
the recommended phase II dose [5]. Few patients participate in
phase I trials (median n = 26 [6]) which limits the
generalisability of the selected dose. Based on the lack of
focus on efficacy, a proportion of patients will show sub-
therapeutic plasma concentrations [7] and be at risk for treat-
ment failure at the early determined MTD. At the same time,
some patients will show toxic plasma concentrations and thus
an increased risk for non-adherence [8] as consequence of
AEs [9].
One strategy to prevent sub-optimal drug concentrations is
the use of therapeutic drug monitoring (TDM), i.e. dosing
based on measured drug exposure [10], guiding OAD dosing
[7, 11–14]. By tailoring drug doses to individual patients, the
proportion of patients with sub-optimal drug concentrations
can be reduced. TDM has already been well-adopted in other
therapeutic areas such as antimicrobial and antiepileptic
therapy [15–17]. Despite its value in oncology becoming
more recognised [18–21], it is still not commonly used in
antineoplastic treatment.
In the following sections, we elaborate on the unexploited
value of TDM in OAD therapy. After introducing various
forms of TDM and TDM for OADs specifically, an overview
of current evidence for drug target concentrations is provided.
Moreover, we describe available PK models, observed PK
exposure, TDM targets and data on exposure-response and
exposure-safety relationships for OADs that are approved by
at least one regulatory agency. Finally, TDM recommenda-
tions are given for OADs, for which targets were established
and TDM has proven feasible.
Therapeutic drug monitoring
Therapeutic drug monitoring (TDM) refers to measuring drug
concentrations to assess if drug concentrations are within the
therapeutic target range and, if necessary, individualise dosing
regimens. An unpredictable dose-exposure relationship, a
small therapeutic window with a defined target concentration,
a high PK and/or pharmacodynamic (PD) IIV and nonlinear
PK are best indicators for a benefit from TDM [7, 22]. The
absence of an exposure-response relationship and high
intraindividual and interoccasion (IOV) PK/PD variability rel-
ative to the IIV are characteristics of drugs unsuitable for
TDM [23, 24] (Supplementary Fig. 2). Several forms of dose
individualisation exist. These are classified as a priori and a
posteriori approaches, depending on the level of
individualisation before treatment initiation [15]. In an a priori
framework, information on both drug and patient characteris-
tics are used to guide initial dosing [25]. Based on established
relationships between patient characteristics and PK parame-
ters, initial dosing can be individualised to patient sub-
populations [26]. However, no individual PK information is
included in an a priori framework, resulting in moderate av-
erage bias and precision [26].
Individual drug concentrations obtained after treatment
start are used in a posteriori TDM [15]. Following the detec-
tion of non-optimal drug concentrations, different procedures
for dose adjustments are possible: in the simplest case, oncol-
ogists will use the drug label, dosing algorithms or nomo-
grams to determine a new dose [27]. Although simple, this
approach requires to abide with the scheduled blood sampling
times and is unsuitable if the patient is not represented by the
population on which drug label or dosing algorithm have been
developed on [28].
Another a posteriori approach involves the collection of 4–
8 blood samples within a dosing interval and the subsequent
calculation of the area under the concentration-time curve
(AUC) [11]. Based on the calculated AUC, individual PK
parameters can be obtained and used for PK calculations to
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determine a more suitable dose. However, dense blood sam-
pling is rarely feasible in clinical practice [29].
Population PK (nonlinear mixed-effects) modelling and
simulation [30] can aid in optimising TDM in multiple ways:
first, PK information from the population can be incorporated
into model parameters during model development. Use of this
information allows to refrain from dense blood sampling in
model-informed precision dosing (MIPD) and often few sam-
ples are enough to obtain sufficiently precise individual PK
estimates [26]. Second, sampling at fixed time points is no
longer necessary and can also be performed prior to steady-
state attainment [26]. As long as actual sampling times are
documented, samples from virtually every time point can be
used for PK analyses in MIPD [26]. Still, there are more and
less informative sampling time points. Optimal design, anoth-
er part of the model-informed dose individualisation process,
can aid in systematically determining the most informative
sampling time point(s) within a given time frame [31].
Finally, Bayesian TDM in MIPD combines model-informed
TDM with the ability to learn and subsequently forecast drug
concentrations at various possible dosing regimens. Similarly
to traditional population PK, the Bayesian approach uses in-
formation from the population to estimate the most likely PK
parameter values for a given drug and population [32]. If
specific patient characteristics influence one or more of the
PK processes, this information can already be used in an a
priori dose selection process. At the beginning of treatment,
when no concentration measurements are available, predicted
PK parameter values for a specific patient will be identical
with the population estimates [29]. As measured drug concen-
trations become available, they are used to refine the patient’s
predicted PK parameter values. The more patient-individual
information (i.e. drug concentrations) is available, the more
weight is set on this information in the parameter estimation
process and the more individual parameter estimates will be
allowed to deviate from the population estimates [29].
Moreover, Bayesian TDM can account for IOV that is lower
than the safe and effective variability [33] and still predict
future doses based on at least two sampling occasions [34,
35]. A disadvantage of Bayesian TDM is the high shrinkage
of predicted individual PK parameters if only a single PK
sample is available: when the population outweighs the indi-
vidual information, individual information on the patient will
get lost as the empirical Bayes estimates shrinks to the typical
population parameters [29]. Moreover, applying Bayesian
TDM requires special knowledge, can be time intensive and
thus difficult to implement in clinical practice.
Sampling minimum plasma concentrations at steady-state
(Cmin,ss) is often performed in clinical practice and, if done
correctly, the currently most precise approach as it avoids
shrinkage of individual information to the population mean.
However, it requires precise information about the patient’s
dosing schedule and good coordination between patient and
treatment team. An easy and time-efficient way to circumvent
the need to sample at Cmin,SS is to account for the difference
between the time of minimum concentrations and time of
measurement and extrapolate based on the time after last dose
and the terminal half-life of the drug. In this method, based on
an algorithm described and validated for imatinib [10], sam-
ples can be taken at random time points in the elimination
phase of the drug and the corresponding Cmin,SS can be calcu-
lated using Eq. (1).
Cmin;SS ¼ Cmeasured*0:5
Dosing Interval h½ −Time after last dose h½ 
Half−life h½  ð1Þ
Of note, this method assumes that Cmeasured is sampled in
the terminal phase of a monoexponential decline. For drugs
with a nonlinear clearance or a short half-life (i.e. dasatinib,
axitinib), an alternative method has to be used. For example,
the Cmin,SS can also be estimated based on a randomly taken
concentration measurement (Cmeasured) and a simulated typical
concentration-time curve, using an existing population PK
model. Based on the ratio of the measured concentration at
tmeasured with the concentration in the simulated PK profile, the
corresponding Cmin,SS in this patient can be estimated [36].
Therapeutic drug monitoring for oral
targeted antineoplastic drugs
Several OAD characteristics suggest individualised dosing:
1 OADs show highly variable drug exposure, caused by IIV
in absorption, distribution, metabolism and excretion
(ADME). Oral bioavailability (BA) differs between and
within agents (i.e. 14–34% in dasatinib and 98% in ima-
tinib) and depends on drug formulation [37], absorption,
first-pass hepatic metabolism and food intake. Moreover,
almost all OADs are metabolised by monooxygenases of
the Cytochrome P450 (CYP) family [3]. Up to 20-fold
variability in expression and activity of CYP3A4 has been
reported, and polymorphisms in the isoenzymes CYP2D6,
CYP2C9 and CYP2C19 additionally contribute to the var-
iable metabolic activity [3]. The activity of CYP enzymes
may be additionally influenced by concomitant adminis-
tration of CYP inducers/inhibitors, environmental factors,
smoking and food intake [3, 38]. Polymorphic transporters
are also involved in the excretion of many agents (i.e.
axitinib, dasatinib and sorafenib) [3].
2 Efficacy is challenging to assess during OAD treatment, as
benefits in clinical outcome parameters such as overall
survival (OS) and progression-free survival (PFS) take
long until evaluable. Objective response rates using CT
scans can be assessed earlier and for a few malignancies,
reliable biomarkers are available (i.e. prostate specific an-
tigen for prostate cancer or complete cytogenic response
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(CCyR) for chronic myeloid leukaemia (CML)).
Furthermore, advances in PKPD modelling allow to use
tumour dynamics in exposure-response analyses [39]. If
an exposure-response relationship has been established,
achieving target concentrations can serve as a proxy for
achieving beneficial outcomes.
As disease progression can be fatal in oncology, treatment
at an exposure above the efficacy threshold should be assured
from the start of treatment or at least achieved as soon as
possible, while individual patient toxicity should be moni-
tored carefully. Furthermore, dose increases should only be
implemented in case of acceptable toxicity and patients with
low exposure and considerable toxicity should be switched to
another treatment option.
Of note, while TDM might be crucial for agents with a
narrow therapeutic window (i.e. pazopanib, sunitinib), it
might be less relevant for agents with a wider therapeutic
window (i.e. erlotinib, osimertinib).
Considering the high costs of OADs, cost-neutral PK-guid-
ed dose interventions to increase exposure, i.e. concomitant
intake with food [40–42], split intake moments [43] or
boosting (i.e. with a CYP3A4 inhibitor), should be considered
before conventional dose increments, particularly in countries
with poor healthcare systems.
For some agents, TDM has already proven feasible [44].
Strong evidence exists for imatinib in CML [18, 45] and gas-
trointestinal stromal tumours (GIST) [46]. Additional com-
pounds for which TDM was feasible in prospective studies
are sunitinib [47], pazopanib [48], tamoxifen [20] and
abiraterone [40]. For other agents, i.e. alectinib [49], axitinib,
crizotinib [49], trametinib [50] and vemurafenib [51–54], a
PK target associated with either efficacy or toxicity has been
established, but not yet evaluated in prospective clinical stud-
ies [13]. Lastly, no information about the value of TDM is
available for some compounds. Most of these are new, and
exposure-response relationships have not been established
yet. For those drugs, we suggest to target the mean/median
exposure as proxy for a PK target, as previously established
PK targets amounted to 85% (± 19%) [14] and 82% (± 17%)
[13] of the mean population exposures in AHDs and KIs,
respectively. This is already applied in the DPOG-TDM study
[55] and similar approaches are suggested by the FDA for
special populations [56–58]. In the DPOG-TDM study [55],
the feasibility, tolerability and efficacy of TDM for 23 differ-
ent OADs is currently being evaluated (www.trialregister.nl;
NL6695)) and preliminary results are promising [59].
The rapid improvement in OAD treatment together with
the continuous development of new compounds poses a chal-
lenge for the timely establishment of viable TDM targets.
While exposure-safety relationships are determined early dur-
ing drug development, observing exposure-response relation-
ships requires extensive time. Accordingly, there is often a
discrepancy between the level of viability of proposed PK/
PD targets and the clinical relevance of a compound. For
example, while imatinib was approved in 2001 [1], the
exposure-response relationships in CML and GIST became
publicly available in 2008 [45] and 2009 [46], respectively.
Sunitinib was first approved in 2006, but the exposure-
response relationship was published in 2010 [60]. Likewise,
pazopanib was approved by the EMA in 2010 and the
exposure-response relationship was first described in 2014
[61].
In the following section, we explore the potential of TDM-
guided dosing to optimise OAD treatment. For each drug, we
searched PubMed and Google Scholar using the terms ‘phar-
macokinetics’, ‘exposure response’, ‘exposure efficacy’, ‘ex-
posure safety’, ‘exposure toxicity’, ‘therapeutic drug monitor-
ing’ and ‘TDM’ together with the respective drug name.
Additionally, we reviewed the respective EMA European
Public Assessment Reports and the FDA Clinical
Pharmacology and Biopharmaceutics Reviews. In
Supplementary Tables 1a-c, KIs, AHDs and other OADs are
summarised together with their molecular target(s), therapeu-
tic indication and date of first approval. Table 1 presents cur-
rent evidence for TDM-guided dosing of OADs. In this table,
each drug is classified according to the level of evidence cur-
rently available for TDM. If there is an established exposure-
response relationship and a PK target, TDM is considered
potentially useful. If additionally, a feasibility study has been
performed, TDM is recommended. If on top of that,
randomised, prospective studies demonstrated a positive ef-
fect of TDM, it is strongly recommended. If there is no evi-
dence for an exposure-response relationship, TDM is consid-
ered exploratory. If there are minimal data on the PK of a drug,
there are more useful targets than plasma concentration or
there is evidence that TDM is not useful, it is not recommend-
ed. Compounds with the highest clinical relevance as mono-
therapy and for which TDM is classified as recommended are
discussed below.
Abiraterone
In an observational study in 61 metastatic castration-resistant
prostate cancer patients, Cmin ≥ 8.4 ng/mL were associated
with a significantly longer PFS compared to Cmin < 8.4 ng/
mL (PFS 7.4 vs 12.2 months, p = 0.044) [62]. This threshold
was later confirmed in a real-world patient cohort (n = 62, PFS
6.1 vs. 16.9 months, p = 0.033) [63]. Yet, at the standard dose
of 1000 mg once daily (QD), 35% and 42% of patients, re-
spectively, did not reach this target [62, 63]. A prospective
study (n = 32) demonstrated that 20 patients (63%) had at least
one Cmin < 8.4 ng/mL with standard care [40]; however, when
a light meal or snack was concomitantly taken with
abiraterone, adequate exposure in 28 patients (87.5%) without
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additional toxicities was achieved [40]. Thus, TDM of
abiraterone and concomitant food intake as a cost-neutral
PK-guided intervention to reach Cmin > 8.4 ng/mL has proven
feasible. Given the absence of an exposure-toxicity relation-
ship, a pragmatic option could be to include concomitant food
intake in the drug label.
Everolimus
In a meta-analysis, it has been reported that a two-fold in-
crease in Cmin was linked to an increased reduction in tumour
size and CSS,min ≥ 10 ng/mL could be used as a cut-off value
[64]. At the same time, CSS,min > 26.3 ng/mL have been asso-
ciated with a 4-fold increased risk of toxicity compared to
CSS,min < 26.3 ng/mL [21]. As the occurrence of AEs seemed
to be associated with high maximum concentrations (Cmax)
[65], Verheijen et al. investigated the potential of alternative
dosing to reduce Cmax-related AEs while maintaining thera-
peutic CSS,min.. In a crossover study in 11 patients, adminis-
tering 5 mg twice daily (BID) instead of 10 mg QD signifi-
cantly reduced everolimus Cmax while CSS,min increased from
9.6 to 13.7 ng/mL [65]. Given the established exposure-
response and exposure-toxicity relationships, we propose to
combine 5 mg BID dosing with TDM to target a therapeutic
window of CSS,min ≥ 10 ng/mL and < 26.3 ng/mL. The devel-
oped population PK model by Combes et al. [66] could serve
as a starting point in a MIPD framework.
Imatinib
Higher frequencies of CCyR and major molecular response
(MMR) have been reported in CML patients with high ima-
tinib Cmin,SS [45, 67]. Current evidence supports the use of a
Cmin,SS ≥ 1000 ng/mL as PK target to achieve improved
CCyR and MMR in CML [68]. Imatinib Cmin,SS > 3000 ng/
mL have been associated with higher rates of AEs [67].
Therefore, a therapeutic window of 1000 ≤ Cmin,SS <
3000 ng/mL seems reasonable [68]. In gastrointestinal stromal
tumours (GIST), one study determined a longer time to dis-
ease progression in patients (n = 73) with CSS,min ≥ 1100 ng/
mL [46]. In another study, a significantly longer PFS was
found in patients with Cmin,SS ≥ 760 ng/mL compared to pa-
tients with Cmin,SS < 760 ng/mL (PFS not reached vs.
56 months, respectively), although this patient population
was not representative of routine clinical practice [69]. The
feasibility of TDM-guided dosing to achieve imatinib
Cmin,SS of 750–1500 ng/mL has been proven in a prospective
randomised controlled trial [18], and several population PK
models [70–72] are available for use in MIPD of imatinib. As
the fraction of patients reaching durable Cmin,SS ≥ 1000 ng/mL
has been reported to be as low as 33.3% [73], individualised
imatinib dosing is highly relevant. As imatinib Cmin have been
reported to decrease during the first 3 months of treatment
[74], it is important to keep measuring imatinib Cmin,SS during
treatment and after dose adjustments.
Pazopanib
An association of CSS,min ≥ 20.5 mg/L with improved PFS
(19.6 vs. 52.0 weeks, p = 0.004) and tumour shrinkage was
found in a retrospective analysis in 177 patients with advanced
renal cell carcinoma (RCC) [61]. This efficacy threshold was
later validated in the adjuvant setting [75] and in a real-life
patient cohort [76]. However, 16–20% [61, 76] of patients do
not reach this threshold and are thus at risk of decreased effi-
cacy. In a prospective feasibility study of individualised
Table 1 Evidence for TDM for targeted oral antineoplastic drugs
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pazopanib dosing, 57% of all patients (n = 30) showed
pazopanib CSS,min < 20 mg/L under standard treatment and
41% of these successfully achieved therapeutic CSS,min upon
dose increases to 1000–1800 mg QD [48]. Furthermore, all
patients who achieved a partial response showed CSS,min ≥
20 mg/mL. In a recent retrospective observational clinical
study in 27 RCC patients, a significant correlation between
pazopanib CSS,min ≥ 20.5 mg/mL and objective response was
established [77]. Based on the evidence for an exposure-
response relationship and the proven feasibility of
individualised dosing, we recommend TDM-guided
pazopanib dosing, targeting plasma CSS,min ≥ 20 mg/mL. A
published population PK model [78] can be used in a MIPD
framework for pazopanib. However, due to a dose-dependent
decrease in the relative BA of pazopanib, conventional dose
increases are an inefficient strategy to increase exposure.
Alternative cost-neutral strategies have been described in lit-
erature. Splitting intake moments (i.e. 400 mg BID instead of
800 mg QD) resulted in a 79% increase in Cmin [79].
Moreover, concomitant intake with food successfully in-
creased exposure as well [42].
Sunitinib
Significant increases in toxicities in patients with sunitinib +
active metabolite SU012662 CSS,min ≥ 100 ng/mL have been
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reported [80, 81]. For RCC patients, an efficacy PK target of
50–100 ng/mL has been proposed in intermittent dosing at
50 mg QD [81]. Exploiting dose linearity, this target was
extrapolated to CSS,min ≥ 37.5 ng/mL for continuous dosing
at 37.5 mg QD in GIST patients [12]. Based on a summary
of exposure-response analyses [60], TDM-guided sunitinib
dosing targeting a sunitinib + SU012662 CSS,min of 50–
100 ng/mL was prospectively tested in a clinical study in 43
patients with advanced solid malignancies [47]. Of the pa-
tients eligible for PK-evaluation (n = 29), 52% (n = 14)
showed sunitinib + SU012662 CSS,min < 50 ng/mL at treat-
ment initiation, and among those, 5 patients reached therapeu-
tic total trough levels after dose escalation without experienc-
ing additional toxicities. These findings underline both the
need and feasibility of TDM-guided sunitinib dosing, for
which a published population PK/PD model can be used
[82]. Biomarkers such as the soluble vascular endothelial
growth factor receptor may provide additional information
on individual response and have been integrated into PK/PD
models [83]. Because of the different half-lives of sunitinib
and SU012662, CSS,min should be calculated separately when
using the log-linear extrapolation method. Due to the long
half-lives and time to reach steady-state, it is important to
collect PK samples in the last treatment week before the off-
treatment period.
Tamoxifen
Compared to higher values, CSS of < 5.97 ng/mL [84] and <
5.2 ng/mL [85] of tamoxifen’s active metabolite endoxifen
have been associated with more additional breast cancer
events and shorter distant relapse-free survival, respectively.
While body weight and age have a significant impact as well
[86], CYP2D6 phenotype accounts for 18–43% of the ob-
served IIV of 40–49% in endoxifen CSS [14]. Considering
this, TDM of endoxifen might be promising to identify pa-
tients with sub-optimal target concentrations [87]. Because no
toxic tamoxifen dose has been identified, dose increases up
until 120 mg QD for patients with endoxifen CSS < 5.97 ng/
mL have been investigated and TDM has proven feasible [20,
88–92]. As it takes about 3 months to attain endoxifen steady
state, we propose to use MIPD for early endoxifen target at-
tainment [93].
Discussion
While exposure-response and exposure-safety relationships
have been observed for many OADs, viable PK targets are
only available for a few. Future clinical and ‘real-world’ stud-
ies are needed to identify clear target ranges associated with
favourable outcome. More PK/PD analyses conducted in
(pre-)clinical development could help to characterise
exposure-response relationships earlier. More focus must also
be dedicated on the establishment of TDM as part of routine
patient care. This might be challenging, as bio-analytical as-
says should be available and a solid logistic system with a
short turn-around time in place. At the Netherlands Cancer
Institute, TDM has been implemented in routine care, and
PK samples are collected at routine visits to the outpatient
clinic. Concentrations of 35 different OADs are measured
weekly using liquid chromatography-tandem mass spectrom-
etry [94–97], treatment recommendations are reported within
24 h to the treating physician and results can be discussed with
patients 1–2 weeks after their visit. This approach is also
emerging in Australia with several OADs being measured
on request with current efficacy-implementation studies un-
derway. Additional data should be prospectively collected (i.e.
in registries) to further investigate the effect of TDM on treat-
ment outcomes. Novel microsampling techniques, i.e. volu-
metric absorptive microsampling (VAMS) [98], could help to
provide the TDM results even before patients visit the outpa-
tient clinic. VAMS allows to precisely sample a small volume
of capillary blood from the fingertip with a dedicated sam-
pling device. After blood collection, the device is dried in
the open air and shipped to a laboratory via regular mail with-
out pre-processing or cooling during transport. Given its easy
and minimally invasive character, this technique shows high
potential: in the future, VAMS samples could be obtained at
home and shipped to a laboratory by patients themselves.
Upon sample analysis, results would be communicated to
the treating oncologist and discussed with the patient at the
next visit. Of note, the disadvantages of VAMS are not fully
elucidated yet. Current limitations are variable analyte recov-
eries dependent on haematocrit [99] and the time-consuming
determination of capillary-to-venous blood conversion fac-
tors, needed to compare measured capillary whole blood with
venous plasma target concentrations [98]. Furthermore, to
make this approach feasible, a well-connected infrastructure
of oncologists, laboratories and PK-specialists must be
available.
Conclusion
In this review, we summarised the opportunities and chal-
lenges associated with TDM of OADs and outlined different
TDM approaches, their respective advantages and disadvan-
tages. We provided strong arguments why routine TDM
should be established as a part of OAD treatment and
reviewed the available evidence for all oral targeted antineo-
plastic drugs currently approved by the EMA and/or FDA.
Finally, we provided an outlook into the future and proposed
a strategy to increase feasibility and acceptance of TDM as
part of routine clinical care.
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